- Revenue Cycle Management
- COVID-19
- Reimbursement
- Diabetes Awareness Month
- Risk Management
- Patient Retention
- Staffing
- Medical Economics® 100th Anniversary
- Coding and documentation
- Business of Endocrinology
- Telehealth
- Physicians Financial News
- Cybersecurity
- Cardiovascular Clinical Consult
- Locum Tenens, brought to you by LocumLife®
- Weight Management
- Business of Women's Health
- Practice Efficiency
- Finance and Wealth
- EHRs
- Remote Patient Monitoring
- Sponsored Webinars
- Medical Technology
- Billing and collections
- Acute Pain Management
- Exclusive Content
- Value-based Care
- Business of Pediatrics
- Concierge Medicine 2.0 by Castle Connolly Private Health Partners
- Practice Growth
- Concierge Medicine
- Business of Cardiology
- Implementing the Topcon Ocular Telehealth Platform
- Malpractice
- Influenza
- Sexual Health
- Chronic Conditions
- Technology
- Legal and Policy
- Money
- Opinion
- Vaccines
- Practice Management
- Patient Relations
- Careers
New drugs in primary care; ‘sham insurance;’ detecting CTE – Morning Medical Update
The top news stories in medicine today.
© everythingpossible - stock.adobe.com
We’re well into 2024, but there’s still much to learn from 2023, including these 13 drugs approved for use in primary care. Catch up now because you know your patients will follow the commercials’ advice to “ask your doctor if (insert drug name here) is right for you.”
The Federal Trade Commission obtained a $195 million judgment and permanent ban on telemarketing and sales of health care products. The feds say Simple Health Plans LLC and CEO Steven J. Dorfman duped consumers into paying for comprehensive health coverage that was anything but.
For years physicians, players and fans have wondered just how badly boxers and football players suffer long-term effects from chronic traumatic encephalopathy due to repeated blows to the head. It has been diagnosed after death, but now researchers say they took “a clear step forward toward diagnosing CTE in life,” according to this study and accompanying news release.
